One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).

Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.

Acute on Chronic Liver Failure

Traditional Chinese Medicine

Hepatitis B

One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.

Chinese herbal medicine

SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.

Control (blank)

302 military hospital of China

Beijing Ditan hospital

Beijing youan hospital

Fuzhou infectious hospital

Xiamen hospital of traditional Chinese medicine

Hubei hospital of traditional Chinese medicine

Tongji hospital, Huazhong university of science and technology

The first affiliated hospital of Hunan university of traditional Chinese medicine

Jilin hepatology hospital

The sixth people's hospital of Shenyang

Shanghai public health clinical center

Shuguang hospital, Shanghai university of traditional Chinese medicine

Chengdu public health clinical center

The second people's hospital of Tianjin

Hangzhou Xixi hospital

Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment

Study on the Optimal Strategy for Acute-on-chronic Liver Failure Combined With Traditional Chinese and Modern Medicine: a Multi-center, Randomized and Controlled Study

transplant free survival at the time point of week 12

transplant free survival at the time point of week 24

compare the MELD score between the two arms. MELD is the abbreviation of model for end-stage liver disease involving serum bilirubin, creatinine, international normalized ratio (INR) and sodium.

compare the Child-Pugh score between the two arms. Child-Pugh score is the panel involving the serum bilirubin, coagulation function, albumin and the complication of hepatic encephalopathy and ascites.

compare the life quality based on WHOQOL-BRIEF between the two arms

incidence of liver related complications of the two arms including infections, encephalopathy, hepatorenal syndrome (HRS), and gastrointestinal bleeding.

Man Gong

Professor

Beijing 302 Hospital

Beijing YouAn Hospital

ShuGuang Hospital

Sun Yat-sen University

Huazhong University of Science and Technology

Fuzhou Infectious Hospital

Public Health Clinical Center of Chengdu

Hepatology hospital of Jilin Province

Shanghai Public Health Clinical Center

Guangxi University of Chinese Medicine

Hubei Hospital of Traditional Chinese Medicine

Beijing Ditan Hospital

Shenzhen traditional Chinese medical hospital

The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Shenzhen Third People's Hospital

Tianjin Second People's Hospital

Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.

Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.

Aneurysmal Subarachnoid Hemorrhage

This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.

Astragalus Membranaceus

Placebo

Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage

Efficacy Study of Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage

evaluating recovery scale percentage at 90 days post discharge following AM treatment for aneurysmal subarachnoid hemorrhage

Interleukin 6, IL-6 in blood and cerebrospinal fluid

Interleukin 1β, IL-1β in blood and cerebrospinal fluid

Tumor Necrosis Factor-α, TNF-α in blood and cerebrospinal fluid

Chun-Chung Chen

Attending Surgeon

China Medical University Hospital

Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.

Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.

Leiomyoma

TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.
High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks.

American Society of Reproductive Medicine Patient Booklet: Uterine Fibroids

School of Chinese Medicine, University of Hong Kong

Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids

A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids

UFS-QOL consists of 37 items to assess the severity of UFs-related symptoms and the quality of life of patients.

The secondary clinical outcome is the clinical response that is defined as a ≥30% baseline-to-endpoint reduction on the symptom severity of transformed UFS-QOL score.

Imaging outcomes will be examined at baseline and endpoint using magnetic resonance imaging (MRI) scan to determine the number, size and density of the uterine fibroids.

two blood samples will be collected from each patient at baseline and at the end of the study, respectively. The collection of blood will be conducted between 08:00 and 09:00 before meal. Sera will be separated and stored at -20ºC until assayed. Serum concentrations of estrogen, progesterone and follicle-stimulating hormone will be measured using chemiluminescent immunoassay (CLIA).

Adverse events will be closely monitored at each visit. All adverse events, reported, elicited or observed, will be recorded on case report form, including the date and time of onset, duration, severity, relationship to study drug, and action taken.

The University of Hong Kong

Stroke

Hemorrhagic Transformation Due to Acute Stroke

Astragalus membranaceus ( AM) at a rate of 3 g three times per day

Chinese Herb Astragalus membranaceus

Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke

The primary outcome measures were the differences in patients' scores on several clinical scales, between baseline (within 7 ± 1 days after the onset of stroke) and week 4 (28 ± 4 days), and between at baseline and week 12 (84 ± 10 days). The scales we used were the Functional Independence Measure scale (FIM), Barthel Index scale (BI), Glasgow Outcome Scale (GOS), and Modified Rankin Scale (MRS). The scores of FIM, BI, GOS, and MRS were assessed by an experienced research nurse.

inflammatory index, which included the levels of C-reactive protein (CRP) and erythrocyte sediment rate (ESR) for venous blood; these were measured at baseline (prior to the first AM dose), and again on the fourth and seventh day of admission; and
Computer tomography (CT) examination, which was done at baseline and on the fourth and seventh days of admission. The ratio of brain edema was calculated by CT (volume of edema divided by blood clot volume)

astragalus amblolepis/blæðing

Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment

Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage

Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids

Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke

The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum